Immunomodulatory drugs in myelodysplastic syndromes.

Immunomodulatory drugs in myelodysplastic syndromes. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Immunomodulatory drugs in myelodysplastic syndromes. Abstract Text:

This review summarises the mechanism of action of immunomodulatory analogues of thalidomide and their use in myelodysplastic syndromes. Thalidomide was found to have a response rate of approximately 20% in these patients. Lenalidomide--which is more potent and less toxic than thalidomide--has been used in three clinical trials and produced the best responses (60 - > 90%) in low- and intermediate-1-risk transfusion-dependent patients with del(5q). The responses are purely erythroid in nature, and are associated with major cytogenetic responses in > 50% of the del(5q) patients. Non-del(5q) low- and intermediate-1-risk transfusion-dependent patients also had a approximately 25% incidence of transfusion independence following therapy with lenalidomide. Median time to response is approximately 4 weeks and 90% of patients respond within 12 weeks. The precise mechanism of action remains unknown but anticytokine, antiangiogenic and immunomodulatory properties are thought to play a role.

Immunomodulatory drugs in myelodysplastic syndromes. Publishing Authors By Initials

For similar peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: monokines: tumor necrosis factor-alpha research

PUBMED ID PMID:

MEDLINE DATE:

Immunomodulatory drugs in myelodysplastic syndromes. Journal Published:

PUBLICATION TYPE: Review

Journal: Expert opinion on investigational drugs

VOLUME: 15

Page Numbers: 805-13

Journal Abbreviation:

ISSN: 1744-7658

DAY: 15

MONTH: Jul

YEAR: 2006

Immunomodulatory drugs in myelodysplastic syndromes. Information

Number of References: 38

LANGUAGE: eng

NlmUniqueID: 9434197

Immunomodulatory drugs in myelodysplastic syndromes. Keywords Mesh Terms:

KEYWORDS: Tumor Necrosis Factor-alpha

MESH TERMS: physiology

Chemical & Substance for Abstract: Immunomodulatory drugs in myelodysplastic syndromes. Information

Substance Name: Thalidomide

Registry Number: 50-35-1

Grant and Affiliation Information for Immunomodulatory drugs in myelodysplastic syndromes.

AFFILIATION: The Radhey Khanna MDS Center, University of Massachusetts Medical Centre, Division of Hematology, Department of Medicine, 364 Plantation Street, LRB 208, Worcester, MA 01605, USA. naomi.galili@umassmed.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Opin Investig Drugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Immunomodulatory drugs in myelodysplastic syndromes Related Publications

• 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis.
• A child with acute appendicitis.
• An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
• Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin.
• Benign fibrous histiocytoma of the rib.
• Comment on: Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists: reply.
• Comparison of two methods (precipitation manual and fully automated enzymatic) for the analysis of HDL and LDL cholesterol.
• Computer audiogram.
• Current treatment options: impact of cytogenetics on the course of myelodysplasia.
• Disorders of sex development (DSDs), their presentation and management in different cultures.
• Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia.
• Facilitating treatment of anxiety disorders in patients with comorbid medical illness.
• Immunomodulatory drugs in myelodysplastic syndromes.
• In situ end labelling of DNA to detect apoptotic cell death in a variety of human tumours.
• In vitro assessment of drug sensitivity in acute nonlymphocytic leukemia.
• Interferon alpha 2a in patients of chronic hepatitis C.
• Localized lesions in secondary syphilis.
• Myocardial revascularization.
• Power Doppler sonography of breast cancer: does vascularity correlate with node status or lymphatic vascular invasion?
• Re: Obtaining previous mammograms for comparison.
• Silent myocardial ischemia.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• Studies on flammability of clothing of burn victims, changes therein and their wearability after a borax rinse.
• The assessment of risk factors for postoperative nausea and vomiting.
• The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial.
• The role of family configuration in early childhood intellectual development in the context of an extended family system in Pakistan.
• Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: Moving toward individualized treatment decision-making.